StandardStandard

The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT. / Sackley, Catherine; Rick, Caroline; Brady, Marian C et al.
Yn: Health Technology Assessment, Cyfrol 28, Rhif 58, 10.2024.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl

HarvardHarvard

Sackley, C, Rick, C, Brady, MC, Burton, C, Jowett, S, Patel, S, Woolley, R, Masterson Algar, P, Nicoll, A, Smith, CH, Abdali, Z, Ives, N, Beaton, G, Dickson, S, Ottridge, R, Nankervis, H & Clarke, CE 2024, 'The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT', Health Technology Assessment, cyfrol. 28, rhif 58. https://doi.org/10.3310/ADWP8001

APA

Sackley, C., Rick, C., Brady, M. C., Burton, C., Jowett, S., Patel, S., Woolley, R., Masterson Algar, P., Nicoll, A., Smith, C. H., Abdali, Z., Ives, N., Beaton, G., Dickson, S., Ottridge, R., Nankervis, H., & Clarke, C. E. (2024). The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT. Health Technology Assessment, 28(58). https://doi.org/10.3310/ADWP8001

CBE

Sackley C, Rick C, Brady MC, Burton C, Jowett S, Patel S, Woolley R, Masterson Algar P, Nicoll A, Smith CH, et al. 2024. The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT. Health Technology Assessment. 28(58). https://doi.org/10.3310/ADWP8001

MLA

VancouverVancouver

Sackley C, Rick C, Brady MC, Burton C, Jowett S, Patel S et al. The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT. Health Technology Assessment. 2024 Hyd;28(58). doi: 10.3310/ADWP8001

Author

Sackley, Catherine ; Rick, Caroline ; Brady, Marian C et al. / The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT. Yn: Health Technology Assessment. 2024 ; Cyfrol 28, Rhif 58.

RIS

TY - JOUR

T1 - The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT

AU - Sackley, Catherine

AU - Rick, Caroline

AU - Brady, Marian C

AU - Burton, Christopher

AU - Jowett, Sue

AU - Patel, Smitaa

AU - Woolley, Rebecca

AU - Masterson Algar, Patricia

AU - Nicoll, Avril

AU - Smith, Christina H

AU - Abdali, Zaineb

AU - Ives, Natalie

AU - Beaton, Gillian

AU - Dickson, Sylvia

AU - Ottridge, Ryan

AU - Nankervis, Helen

AU - Clarke, Carl E

PY - 2024/10

Y1 - 2024/10

N2 - Background: Speech impairments are common with Parkinson’s disease (reported prevalence 68%), increasing conversational demands, reliance on family and social withdrawal.Objective(s): The PD COMM trial compared the clinical and cost-effectiveness of two speech and language therapy approaches: Lee Silverman Voice Treatment LOUD and National Health Service speech and language therapy for the treatment of speech or voice problems in people with Parkinson’s disease to no speech and language therapy (control) and against each other.Design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Participants were randomised in a 1 : 1 : 1 ratio to control, National Health Service speech and language therapy or Lee Silverman Voice Treatment LOUD via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Mixed-methods process and health economic evaluations were conducted.Setting: United Kingdom outpatient and home settings.Participants: People with idiopathic Parkinson’s disease, with self-reported or carer-reported speech or voice problems. We excluded people with dementia, laryngeal pathology and those within 24 months of previous speech and language therapy.Interventions: The Lee Silverman Voice Treatment LOUD intervention included maximum effort drills and high-effort speech production tasks delivered over four 50-minute therapist-led personalised sessions per week, for 4 weeks with prescribed daily home practice. National Health Service speech and language therapy content and dosage reflected local non-Lee Silverman Voice Treatment speech and language therapy practices, usually 1 hour, once weekly, for 6 weeks. Trained, experienced speech and language therapists or assistants provided interventions. The control was no speech and language therapy until the trial was completed.Main outcome measures: Primary outcome: Voice Handicap Index total score at 3 months. Secondary outcomes: Voice Handicap Index subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5L; ICEpop Capabilities Measure for Older Adults; Parkinson’s Disease Questionnaire – Carers; resource utilisation; and adverse events. Assessments were completed pre-randomisation and at 3, 6 and 12 months post randomisation.Results: Three hundred and eighty-eight participants were randomised to Lee Silverman Voice Treatment LOUD (n = 130), National Health Service speech and language therapy (n = 129) and control (n = 129). The impact of voice problems at 3 months after randomisation was lower for Lee Silverman Voice Treatment LOUD participants than control [−8.0 (99% confidence interval: −13.3, −2.6); p = 0.001]. There was no evidence of improvement for those with access to National Health Service speech and language therapy when compared to control [1.7 (99% confidence interval: −3.8, 7.1); p = 0.4]. Participants randomised to Lee Silverman Voice Treatment LOUD reported a lower impact of their voice problems than participants randomised to National Health Service speech and language therapy [99% confidence interval: −9.6 (−14.9, −4.4); p < 0.0001]. There were no reports of serious adverse events. Staff were confident with the trial interventions; a range of patient and therapist enablers of implementing Lee Silverman Voice Treatment LOUD were identified. The economic evaluation results suggested Lee Silverman Voice Treatment LOUD was more expensive and more effective than control or National Health Service speech and language therapy but was not costeffective with incremental cost-effectiveness ratios of £197,772 per quality-adjusted life-year gained and £77,017 per quality-adjusted life-year gained, respectively.Limitations: The number of participants recruited to the trial did not meet the pre-specified power.Conclusions: People that had access to Lee Silverman Voice Treatment LOUD described a significantly greater reduction in the impact of their Parkinson’s disease-related speech problems 3 months after randomisation compared to people that had no speech and language therapy. There was no evidence of a difference between National Health Service speech and language therapy and those that received no speech and language therapy. Lee Silverman Voice Treatment LOUD resulted in a significantly lower impact of voice problems compared to National Health Service speech and language therapy 3 months after randomisation which was still present after 12 months; however, Lee Silverman Voice Treatment LOUD was not found to be cost-effective. Future work: Implementing Lee Silverman Voice Treatment LOUD in the National Health Service and identifying alternatives to Lee Silverman Voice Treatment LOUD for those who cannot tolerate it. Investigation of less costly alternative options for Lee Silverman Voice Treatment delivery require investigation, with economic evaluation using a preference-based outcome measure that captures improvement in communication.Study registration: This study is registered as ISRCTN12421382.Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 10/135/02) and is published in full in Health Technology Assessment; Vol. 28, No. 58. See the NIHR Funding and Awards website for further award information

AB - Background: Speech impairments are common with Parkinson’s disease (reported prevalence 68%), increasing conversational demands, reliance on family and social withdrawal.Objective(s): The PD COMM trial compared the clinical and cost-effectiveness of two speech and language therapy approaches: Lee Silverman Voice Treatment LOUD and National Health Service speech and language therapy for the treatment of speech or voice problems in people with Parkinson’s disease to no speech and language therapy (control) and against each other.Design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Participants were randomised in a 1 : 1 : 1 ratio to control, National Health Service speech and language therapy or Lee Silverman Voice Treatment LOUD via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Mixed-methods process and health economic evaluations were conducted.Setting: United Kingdom outpatient and home settings.Participants: People with idiopathic Parkinson’s disease, with self-reported or carer-reported speech or voice problems. We excluded people with dementia, laryngeal pathology and those within 24 months of previous speech and language therapy.Interventions: The Lee Silverman Voice Treatment LOUD intervention included maximum effort drills and high-effort speech production tasks delivered over four 50-minute therapist-led personalised sessions per week, for 4 weeks with prescribed daily home practice. National Health Service speech and language therapy content and dosage reflected local non-Lee Silverman Voice Treatment speech and language therapy practices, usually 1 hour, once weekly, for 6 weeks. Trained, experienced speech and language therapists or assistants provided interventions. The control was no speech and language therapy until the trial was completed.Main outcome measures: Primary outcome: Voice Handicap Index total score at 3 months. Secondary outcomes: Voice Handicap Index subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5L; ICEpop Capabilities Measure for Older Adults; Parkinson’s Disease Questionnaire – Carers; resource utilisation; and adverse events. Assessments were completed pre-randomisation and at 3, 6 and 12 months post randomisation.Results: Three hundred and eighty-eight participants were randomised to Lee Silverman Voice Treatment LOUD (n = 130), National Health Service speech and language therapy (n = 129) and control (n = 129). The impact of voice problems at 3 months after randomisation was lower for Lee Silverman Voice Treatment LOUD participants than control [−8.0 (99% confidence interval: −13.3, −2.6); p = 0.001]. There was no evidence of improvement for those with access to National Health Service speech and language therapy when compared to control [1.7 (99% confidence interval: −3.8, 7.1); p = 0.4]. Participants randomised to Lee Silverman Voice Treatment LOUD reported a lower impact of their voice problems than participants randomised to National Health Service speech and language therapy [99% confidence interval: −9.6 (−14.9, −4.4); p < 0.0001]. There were no reports of serious adverse events. Staff were confident with the trial interventions; a range of patient and therapist enablers of implementing Lee Silverman Voice Treatment LOUD were identified. The economic evaluation results suggested Lee Silverman Voice Treatment LOUD was more expensive and more effective than control or National Health Service speech and language therapy but was not costeffective with incremental cost-effectiveness ratios of £197,772 per quality-adjusted life-year gained and £77,017 per quality-adjusted life-year gained, respectively.Limitations: The number of participants recruited to the trial did not meet the pre-specified power.Conclusions: People that had access to Lee Silverman Voice Treatment LOUD described a significantly greater reduction in the impact of their Parkinson’s disease-related speech problems 3 months after randomisation compared to people that had no speech and language therapy. There was no evidence of a difference between National Health Service speech and language therapy and those that received no speech and language therapy. Lee Silverman Voice Treatment LOUD resulted in a significantly lower impact of voice problems compared to National Health Service speech and language therapy 3 months after randomisation which was still present after 12 months; however, Lee Silverman Voice Treatment LOUD was not found to be cost-effective. Future work: Implementing Lee Silverman Voice Treatment LOUD in the National Health Service and identifying alternatives to Lee Silverman Voice Treatment LOUD for those who cannot tolerate it. Investigation of less costly alternative options for Lee Silverman Voice Treatment delivery require investigation, with economic evaluation using a preference-based outcome measure that captures improvement in communication.Study registration: This study is registered as ISRCTN12421382.Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 10/135/02) and is published in full in Health Technology Assessment; Vol. 28, No. 58. See the NIHR Funding and Awards website for further award information

U2 - 10.3310/ADWP8001

DO - 10.3310/ADWP8001

M3 - Article

VL - 28

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 58

ER -